Latest news with #AllClear
Scotsman
5 days ago
- Scotsman
Insurance red alert as 8 in 10 UK holidaymakers cut back on summer holiday spend
As the summer holiday season approaches its peak, new research from AllClear Travel Insurance reveals a troubling shift in public perception: more British travellers are downgrading or removing their travel insurance cover altogether - with cost pressures driving risky decisions and misunderstandings about protection on holiday. Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... A new AllClear survey of 2,000 adults revealed that four in five UK holidaymakers (80%) say they will be cutting corners on areas of spend to have a cheaper summer holiday this year. And while hand luggage hacks and budget flights are becoming the norm, an increasing number of people are gambling on their health and finances - by either skipping travel insurance or choosing the cheapest cover available. The number of people planning to travel abroad without any insurance has jumped from 9% to 15% since last summer and, for those that will take out travel insurance, there's a significant upturn in the number of travellers opting for the cheapest travel policies available - rising from 20% to 30% in just 12-months. Advertisement Hide Ad Advertisement Hide Ad Among those with pre-existing medical conditions, who are statistically more likely to need medical support abroad, the trend is even starker: Garry Nelson 21% say they'll travel without any cover; 30% will buy the cheapest policy available; 13% admit they wouldn't disclose their full medical history in order to keep their policy premium down; For short haul holidays, one in five (20%) say they would skip travel insurance altogether -despite the potential for substantial medical bills. 'These decisions aren't just about money - they're about misunderstanding,' says Garry Nelson, Head of Corporate Affairs at AllClear Travel Insurance. 'Too many people are treating travel insurance like a commodity, rather than a safety net. But the reality is, you only realise the value of comprehensive travel cover when something goes wrong.' AllClear's new data paints a clear picture of how different groups are approaching travel insurance in 2025: Over 55s - the most safety-conscious abroad False economy Only 9% plan to travel abroad uninsured. 68% say they will always declare their full medical history when buying travel cover. Those looking to make savings on holiday costs will do this by going self-catering (38%) or using public transport at resort (36%) — not by risking their health or finances. People with Medical Conditions taking unnecessary risks More than one in five (21%) say they will travel abroad with no cover in order to trim overall holiday spend. Many underestimate the risk or wrongly assume that policies will still pay out even if they haven't disclosed key medical details when buying travel cover. Less than one in two are aware non-declaration of medical conditions risks invalidating their travel insurance (49%). Under 25s making the big cutbacks The age group most likely to take steps to cut back holiday spend this year (93%). Three in 10 (30%) would look to buy the cheapest travel cover. They were also the age group most likely to travel abroad with no cover at all (19%). This group is also more likely to cut out travel insurance before reigning in spend on dining out (14%), taking less luggage (16%), or going for a cheaper resort (15%). 22% believe 'all travel policies are broadly the same.'
Sydney Morning Herald
6 days ago
- Health
- Sydney Morning Herald
Australian cancer breakthrough could mean an end to relapse for thousands, including Colette
Collette Chase says the hardest part of finishing breast cancer treatment is the fear that the disease will return. 'Even Princess Kate said it recently ... you just live in a ball of anxiety,' said Chase, who is in her 50s. 'People will say to you, 'Ah look, you could get hit by a bus tomorrow'. I'd choose that because if this comes back metastatic as stage 4, what's [the treatment] going to do to me?' Australian scientists are hoping to alleviate this fear and halve breast cancer recurrence by utilising new technology that allows them to find, isolate and study the rare cancer cells lying dormant in people's bones. Loading Garvan Institute researchers have discovered how to find the previously undetectable cells, and their technology will be used in a $25 million research project to learn how they hide, how they are different, why they 'wake up' and how they can be destroyed beforehand. It has potential to be applied to our understanding of why other cancers return. Despite dramatically improved survival rates, about 15 per cent of breast cancer patients will experience a recurrence of it within 10 years, which can be fatal. This is because rare 'seeds' of cancer can conceal themselves, most often in bones, and remain dormant for years, sometimes decades. A team of 60 researchers from seven Australian institutes and organisations, the Universities of Sydney and Newcastle, multiple Australian hospitals and universities, plus Yale and Washington universities, have been awarded the National Breast Cancer Foundation's biggest grant for the project, dubbed AllClear.
The Age
6 days ago
- Health
- The Age
Australian cancer breakthrough could mean an end to relapse for thousands, including Colette
Collette Chase says the hardest part of finishing breast cancer treatment is the fear that the disease will return. 'Even Princess Kate said it recently ... you just live in a ball of anxiety,' said Chase, who is in her 50s. 'People will say to you, 'Ah look, you could get hit by a bus tomorrow'. I'd choose that because if this comes back metastatic as stage 4, what's [the treatment] going to do to me?' Australian scientists are hoping to alleviate this fear and halve breast cancer recurrence by utilising new technology that allows them to find, isolate and study the rare cancer cells lying dormant in people's bones. Loading Garvan Institute researchers have discovered how to find the previously undetectable cells, and their technology will be used in a $25 million research project to learn how they hide, how they are different, why they 'wake up' and how they can be destroyed beforehand. It has potential to be applied to our understanding of why other cancers return. Despite dramatically improved survival rates, about 15 per cent of breast cancer patients will experience a recurrence of it within 10 years, which can be fatal. This is because rare 'seeds' of cancer can conceal themselves, most often in bones, and remain dormant for years, sometimes decades. A team of 60 researchers from seven Australian institutes and organisations, the Universities of Sydney and Newcastle, multiple Australian hospitals and universities, plus Yale and Washington universities, have been awarded the National Breast Cancer Foundation's biggest grant for the project, dubbed AllClear.
Perth Now
6 days ago
- Health
- Perth Now
Ambitious project aims to stop breast cancer recurring
An ambitious goal to halve the number of deaths from breast cancer could be one step closer after a landmark investment in a medical research program. The National Breast Cancer Foundation has awarded a $25 million grant to researchers at the Garvan Institute of Medical Research in Sydney. The grant will fund the "AllClear" program, a research project focused on stopping recurrence of breast cancer, led by Garvan Institute Associate Professor Christine Chaffer. It will be vitally important for patients such as Amy Busdon, a mother of three girls, who was diagnosed in early 2024 just before her 40th birthday. With no family history, she was shocked when, the same week she was diagnosed, her mum called to tell her she too had breast cancer and would be undergoing treatment. "(The diagnosis) is just shattering in an instant," Ms Busdon said. "Everything just flashes before you. You think of the girls and your husband and start planning their life without you in it." In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. For some survivors, the breast cancer cells hide quietly in the body, commonly in the bone, and can reappear years or decades after the initial treatment. About 15 per cent of people will experience a cancer recurrence, which can often be life threatening. "We want to understand these cells and improve how we can find them because they are the ones we need to eradicate to stop recurrence and prevent patients from metastasis which can be really hard to treat," Prof Chaffer told AAP. "The research will also help us to understand what makes those cells different and work on treatments to eradicate dormant cells." The AllClear team will study cancer cells in the bone to understand how they hide, how they are different to cells in the primary tumour and why current treatments may fail. The research will help develop new therapies and fast-track their testing through clinical trials. Patients who have faced and treated a breast cancer diagnosis cannot currently be told whether their cancer is likely to recur, which Prof Chaffer said could cause enormous stress. "The fear of recurrence is huge and patients are living with that after cancer diagnosis - you can't underestimate the detrimental side effects of that fear," she said. For Ms Busdon, it's something she thinks about every day. "I've got three beautiful girls and I want to make sure I'm here for them when they grow up," she said. "Breast cancer research is so important and it gives me a lot of hope." The Garvan Institute research program aims to help patients know if they are "all clear" of cancer cells which could recur. "Being able to predict that will be a world a first," Prof Chaffer said. Australia's leading not-for-profit organisation which funds breast cancer research, NBCF has the ambitious goal of zero deaths from the disease. The death rate from breast cancer in Australia had reduced by 40 per cent in the past three decades which showed the needle could be moved, NBCF chief executive Cleola Anderiesz said. "We didn't improve this rate simply by good luck. It's been because of significant investment in research," Dr Anderiesz said. "The NBCF is completely community funded and our ability to invest in this extraordinary research is due to the generosity of our supporters."
West Australian
6 days ago
- Health
- West Australian
Ambitious project aims to stop breast cancer recurring
An ambitious goal to halve the number of deaths from breast cancer could be one step closer after a landmark investment in a medical research program. The National Breast Cancer Foundation has awarded a $25 million grant to researchers at the Garvan Institute of Medical Research in Sydney. The grant will fund the "AllClear" program, a research project focused on stopping recurrence of breast cancer, led by Garvan Institute Associate Professor Christine Chaffer. It will be vitally important for patients such as Amy Busdon, a mother of three girls, who was diagnosed in early 2024 just before her 40th birthday. With no family history, she was shocked when, the same week she was diagnosed, her mum called to tell her she too had breast cancer and would be undergoing treatment. "(The diagnosis) is just shattering in an instant," Ms Busdon said. "Everything just flashes before you. You think of the girls and your husband and start planning their life without you in it." In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. For some survivors, the breast cancer cells hide quietly in the body, commonly in the bone, and can reappear years or decades after the initial treatment. About 15 per cent of people will experience a cancer recurrence, which can often be life threatening. "We want to understand these cells and improve how we can find them because they are the ones we need to eradicate to stop recurrence and prevent patients from metastasis which can be really hard to treat," Prof Chaffer told AAP. "The research will also help us to understand what makes those cells different and work on treatments to eradicate dormant cells." The AllClear team will study cancer cells in the bone to understand how they hide, how they are different to cells in the primary tumour and why current treatments may fail. The research will help develop new therapies and fast-track their testing through clinical trials. Patients who have faced and treated a breast cancer diagnosis cannot currently be told whether their cancer is likely to recur, which Prof Chaffer said could cause enormous stress. "The fear of recurrence is huge and patients are living with that after cancer diagnosis - you can't underestimate the detrimental side effects of that fear," she said. For Ms Busdon, it's something she thinks about every day. "I've got three beautiful girls and I want to make sure I'm here for them when they grow up," she said. "Breast cancer research is so important and it gives me a lot of hope." The Garvan Institute research program aims to help patients know if they are "all clear" of cancer cells which could recur. "Being able to predict that will be a world a first," Prof Chaffer said. Australia's leading not-for-profit organisation which funds breast cancer research, NBCF has the ambitious goal of zero deaths from the disease. The death rate from breast cancer in Australia had reduced by 40 per cent in the past three decades which showed the needle could be moved, NBCF chief executive Cleola Anderiesz said. "We didn't improve this rate simply by good luck. It's been because of significant investment in research," Dr Anderiesz said. "The NBCF is completely community funded and our ability to invest in this extraordinary research is due to the generosity of our supporters."
